KidneyCure Raises $4m for New Kidney Disease Treatment
KidneyCure, the Israeli cell therapy company based in Tel Aviv, is developing treatment for end-stage renal disease. This innovative company recently announced the financial support of new investors, Aurum Ventures, controlled by Morris Kahn, and Direct Insurance –Financial Investments. Altogether, the addition of these two investors brings the total capital raised by KidneyCure to $4 million.
KidneyCure uses the patient’s cells to produce a “mini-kidney” that supports the activity of the diseased kidney. The goal of this therapy is to postpone the need for dialysis or a kidney transplant.
The entrepreneur and developer of KidneyCure’s cutting-edge product is Prof. Benjamin Dekel, Head of the Pediatric Stem cell Research Institute and the Director of the Division of Pediatric Nephrology at the Edmond and Lily Safra Children’s Hospital, Sheba Medical Center.